$EDSA: @EdesaBiotech – Positive Interim Efficacy Analysis For EB01 Phase 2b Trial In Allergic Contact Dermatitis… – https://t.co/DUnY5VckGv by @DavidBautz pic.twitter.com/k3t8EizaRZ
— Zacks SCR (@ZacksSmallCap) June 4, 2021
$EDSA: @EdesaBiotech – Positive Interim Efficacy Analysis For EB01 Phase 2b Trial In Allergic Contact Dermatitis… – https://t.co/DUnY5VckGv by @DavidBautz pic.twitter.com/k3t8EizaRZ
— Zacks SCR (@ZacksSmallCap) June 4, 2021